Related Experiment Video
Updated: May 4, 2026
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
Evaluation of different anti-asthmatic drugs on cooling-induced bronchoconstriction
1Department of Biomedical Sciences, College of Nursing, Public Authority for Applied Education and Training, Kuwait, Kuwait.
Background:
Inhalation of cold air is a well-recognized cause of bronchoconstriction in asthmatics. Sudden changes in weather temperature outdoors and indoors due to the extensive use of air conditioning in Kuwait is an important existing problem.
Objectives:
The aim of this study was to determine the most effective anti-asthmatic drugs for preventing or reversing cooling-induced contraction (CIC).
Methods:
We recorded isometric tension from tracheal strips, and bronchiolar rings were prepared from male Merino sheep in organ baths during stepwise cooling. CIC was tested before and after addition of various standard agents. Disodium cromoglycate (DSG), methyl prednisolone, atropine, aminophylline, isoprenaline and adrenaline were examined in two cases. The first was before cooling and the second was after cooling induced the maximum bronchoconstriction.
Results:
Cooling to 20°C induced a rapid and reproducible contraction in ovine tracheal and bronchial preparations. On readjustment to 37°C, the tone returned rapidly to basal level. DSG, methyl prednisolone and atropine did not prevent or reverse the CIC. Aminophylline prevented CIC by 70%. It inhibited the peak of cooling response by 70%. β-agonists (isoprenaline and adrenaline) abolished the CIC, and they also rapidly and totally reversed the cooling effect when added at the peak of bronchoconstriction.
Conclusions:
These results proved that β-agonists are the drugs of choice in preventing the bronchoconstriction before exposure to cold environment and also completely reversing the bronchoconstriction induced after cooling exposure.
Related Concept Videos
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
01:17Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
01:24Antiasthma Drugs: Methylxanthines
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:20Antiasthma Drugs: Muscarinic Receptor Antagonists
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...